

1 Growth and neurite stimulating effects of the neonicotinoid pesticide
2 clothianidin on human neuroblastoma SH-SY5Y cells

3
4 Tetsushi Hirano^{a,*}, Satsuki Minagawa^a, Yukihiro Furusawa^b, Tatsuya Yunoki^c,
5 Yoshinori Ikenaka^{d,e}, Toshifumi Yokoyama^f, Nobuhiko Hoshi^f, Yoshiaki Tabuchi^a

6
7 ^a*Life Science Research Center, University of Toyama, Toyama, Toyama, Japan*

8 ^b*Department of Liberal Arts and Sciences, Toyama Prefectural University, Toyama, Toyama,*
9 *Japan*

10 ^c*Department of Ophthalmology, Graduate School of Medicine and Pharmaceutical Sciences,*
11 *University of Toyama, Toyama, Toyama, Japan*

12 ^d*Laboratory of Toxicology, Department of Environmental Veterinary Sciences, Faculty of*
13 *Veterinary Medicine, Hokkaido University, Sapporo, Hokkaido, Japan*

14 ^e*Water Research Group, Unit for Environmental Sciences and Management, North-West*
15 *University, Potchefstroom, South Africa*

16 ^f*Department of Animal Science, Graduate School of Agricultural Science, Kobe University,*
17 *Kobe, Hyogo, Japan*

18
19 *Abbreviations:* nAChR, nicotinic acetylcholine receptor; CTD, clothianidin; ACE,
20 acetamiprid; IMI, imidacloprid; NOAEL, no observed adverse effect level; DH β E,
21 dihydro- β -erythroidine; MEC, Mecamylamine; MLA, methyllycaconitin

22 *Corresponding author at: Life Science Research Center, University of Toyama, 2630
23 Sugitani, Toyama 930-0194, Japan.

24 *E-mail address:* thirano@cts.u-toyama.ac.jp (T. Hirano).

25 **ABSTRACT**

26 Neonicotinoids are one of most widely used pesticides targeting nicotinic acetylcholine
27 receptors (nAChRs) of insects. Recent epidemiological evidence revealed increasing amounts
28 of neonicotinoids detected in human samples, raising the critical question of whether
29 neonicotinoids affect human health. We investigated the effects of a neonicotinoid pesticide
30 clothianidin (CTD) on human neuroblastoma SH-SY5Y cells as *in vitro* models of human
31 neuronal cells. Cellular and functional effects of micromolar doses of CTD were evaluated by
32 changes in cell growth, intracellular signaling activities and gene expression profiles. We
33 examined further the effects of CTD on neuronal differentiation by measuring neurite
34 outgrowth. Exposure to CTD (1–100 μ M) significantly increased the number of cells within
35 24 hours of culture. The nAChRs antagonists, mecamylamine and SR16584, inhibited this
36 effect, suggesting human α 3 β 4 nAChRs could be targets of neonicotinoids. We observed a
37 transient intracellular calcium influx and increased phosphorylation of extracellular
38 signal-regulated kinase 1/2 shortly after exposure to CTD. Transcriptome analysis revealed
39 that CTD down-regulated genes involved in neuronal function (e.g., formation of filopodia
40 and calcium ion influx) and morphology (e.g., axon guidance signaling and cytoskeleton
41 signaling); these changes were reflected by a finding of increased neurite length during
42 neuronal differentiation. These findings provide novel insight into the potential risks of
43 neonicotinoids to the human nervous system.

44
45 *Keywords:* Neonicotinoid; Pesticide; Clothianidin; Neuroblastoma cell; Nicotinic
46 acetylcholine receptor; Intracellular signaling.

1 47 **1. Introduction**

2
3 48 Neonicotinoids are the most recent and widely used class of pesticides to control harmful
4
5
6 49 insects in the world. With expanding use of the pesticides in farming, multiple neonicotinoids
7
8
9 50 are present in most vegetables, fruits and crops at parts-per-billion concentrations (Chen et al.,
10
11 51 2014; Ikenaka et al., 2018). In fact, neonicotinoids were detected in urine samples from most
12
13
14 52 adults and children (Ueyama et al., 2015; Ikenaka et al., 2019) and the urinary concentration
15
16 53 of total neonicotinoids in Japanese children has been reported to be in the hundreds-level
17
18
19 54 nanomolar (Osaka et al., 2016). Neonicotinoids act as nicotinic acetylcholine receptor
20
21 55 (nAChR) agonists with as much as hundreds fold greater affinity for insect nAChRs than for
22
23
24 56 mammalian receptors (Tomizawa and Casida, 2005); however, adverse effects on
25
26 57 physiological function of non-target vertebrates have been reported over the last decade
27
28
29 58 (Hoshi et al., 2014; Gibbons et al., 2015; Wang et al., 2018). *In vitro* studies have shown that
30
31
32 59 potency and specificity for mammalian nAChRs are critically different among types of
33
34 60 neonicotinoids (Casida, 2018). In particular, Kimura-Kuroda et al. (2012) firstly showed that
35
36
37 61 acetamiprid (ACE) and imidacloprid (IMI), earlier chloropyridylmethyl neonicotinoids,
38
39 62 caused neural excitation in cerebellar cells from neonatal rats mediated by nAChRs. These
40
41
42 63 ligand-gated ion channel receptors play a variety of roles in multiple areas of the mammalian
43
44 64 brain, including not only cholinergic transmission but also neural excitability and synaptic
45
46
47 65 plasticity (Gotti, et al., 2006; Dani and Bertrand, 2007). Thus, there is increasing concern
48
49 66 about the risks of neonicotinoids on the central nervous system in mammals.

50
51
52 67 Recent rodent studies indicated that a variety of neonicotinoids have neurobehavioral
53
54
55 68 effects on mammals depending on the timing of exposure. We previously reported that at or
56
57 69 below the no observed adverse effect level (NOAEL) of a later-developed
58
59
60 70 chlorothiazolymethyl neonicotinoid, clothianidin (CTD) resulted in anxiety-like behavior

1 71 and human-audible vocalization in a novel environment in mature mice (Hirano et al., 2015,
2
3 72 2018). Gestational and postnatal exposure of an early-type of neonicotinoid, ACE induced
4
5 73 behavioral changes including increasing of sexual and attacking behavior in mature offspring
6
7
8 74 (Sano et al., 2016), whereas IMI decreased social aggression behavior (Burke et al., 2018). In
9
10
11 75 addition, pre- and postnatal exposure to the latest neonicotinoid, dinotefuran increased the
12
13 76 number of dopaminergic and serotonergic neurons in the midbrain of mature mice (Takada et
14
15
16 77 al., 2018; Yoneda et al., 2018). Although no common effects associated with the
17
18 78 developmental neurotoxicity were observed among neonicotinoids (Sheets et al., 2016),
19
20
21 79 differentiative neurons in the mammalian developing brain could be a potential target of
22
23
24 80 neonicotinoids.

25
26 81 It has been noted that the amount and detection rate of neonicotinoids in human-derived
27
28
29 82 samples are increasing gradually every year (Ueyama et al., 2015). Although human
30
31
32 83 population studies reported that environmental exposure to neonicotinoids associated with
33
34 84 adverse neurological outcomes such as memory loss and finger tremor, experimental studies
35
36 85 of risks of neonicotinoids in humans are still far from sufficient (Cimino et al., 2017). Most
37
38
39 86 toxicological data for evaluating the effects of neonicotinoids were obtained from *in vitro* and
40
41
42 87 *in vivo* studies using rats and mice as animal models; however, there are evolutionary
43
44 88 differences in the amino acid sequence of nAChRs subunits between rodents and human
45
46
47 89 (Tsunoyama and Gojobori, 1998; Stokes et al., 2015). Therefore, the intensity and dose
48
49
50 90 responses of nAChRs to nicotinic agonists can be different across species (Papke and Porter
51
52 91 Papke, 2002; Anderson et al., 2008), suggesting that there is some uncertainty to predict the
53
54 92 risk of modulating the function of human-type nAChRs from other species.

55
56
57 93 In the present study, we focused on CTD which has been banned in the European Union
58
59
60 94 since 2013; however, it became a first-line pesticide for farming in many countries.

1 95 Intraperitoneally-administered CTD was immediately absorbed and reached throughout the
2
3 96 body in mice including the brain at least a few hours (Ford and Casida, 2006). The aim of the
4
5 97 present study is to provide novel experimental data for assessing whether CTD could affect
6
7
8 98 human nervous system structure or function, using a human neuroblastoma cell line
9
10
11 99 SH-SY5Y cells known to have high expression levels of neuronal types of nAChRs that
12
13 100 contain $\alpha 3$, $\alpha 7$, $\beta 2$, and $\beta 4$ subunits (Lukas et al., 1993; Groot Kormelink and Luyten, 1997;
14
15
16 101 Kovalevich and Langford, 2013) instead of animal models. We investigated the potential
17
18 102 effects of CTD on cell growth and development, and examined mechanisms of action
19
20
21 103 focusing on intracellular signaling and gene expression profiles.
22
23
24 104

26 105 **2. Materials and methods**

28 106 *2.1. Cell culture and chemical treatments*

30
31 107 Human neuroblastoma SH-SY5Y cells (ECACC, No. 94030304) were maintained in
32
33
34 108 Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS), 100
35
36 109 U/ml penicillin and 100 $\mu\text{g/ml}$ streptomycin at 37°C in humidified air with 5% CO₂.
37
38
39 110 Clothianidin (CTD; purity > 99.8%; Sigma-Aldrich, St. Louis, MO, USA),
40
41 111 dihydro- β -erythroidine hydrobromide (DH β E; Tocris Bioscience, Ellisville, MO, USA) and
42
43
44 112 SR 16584 (Cayman Chemical Co., Ann Arbor, MI, USA) were dissolved in dimethyl
45
46 113 sulfoxide (DMSO). Mecamylamine hydrochloride (MEC; Sigma-Aldrich) and
47
48
49 114 methyllycaconitine citrate (MLA; Cayman Chemical Co.) were dissolved in sterilized water.
50
51
52 115 In all experiments, cells treated with corresponding vehicle (0.1% v/v) were used as a control.
53
54 116

57 117 *2.2. Cell growth assay*

59 118 For cell counting assays, cells were subcultured in 12-well plates at a seeding density $5.0 \times$

1 119 10^4 cells/mL with 1 mL of the culture medium for 24 h, and then exposed to 1 or 100 μM
2
3 120 CTD with reference to previous *in vitro* studies (Kimura-Kuroda et al., 2012; Christen et al.,
4
5 121 2017). After washing once with phosphate-buffered saline (PBS) and subsequent
6
7
8 122 trypsinization, the number of cells was counted using a hemacytometer on Day 1 and 2. For
9
10
11 123 antagonist assays, cells were exposed to nAChR antagonists concomitantly with 100 μM
12
13 124 CTD and counted on Day 1. For microplate assays, cells were plated into 96-well plates at a
14
15
16 125 seeding density 5.0×10^4 cells/mL with 100 μL of the culture medium for 24 h, and then
17
18
19 126 exposed to various concentrations of CTD (1 nM to 100 μM) for 24 h. Cells were then
20
21 127 incubated with
22
23 128 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium
24
25
26 129 (WST-8; Dojindo Laboratories, Kumamoto, Japan) solution for 3 h and the absorbance at 450
27
28
29 130 nm was measured by a BioRad 680 microplate reader (BioRad, Hercules, CA, USA).
30

31 131

34 132 2.3. *Fluo-4 calcium flux assay*

36 133 Changes in intracellular calcium concentration were measured with a fluo-4 kit (Dojindo
37
38
39 134 Laboratories) according to the manufacturer's instructions. Briefly, semi-confluent cells in a
40
41
42 135 96-well microplate were loaded with 10 μM Fluo-4 AM in 100 μL of recording buffer [20
43
44 136 mM HEPES buffer containing 115 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl_2 , 1.8 mM CaCl_2 ,
45
46
47 137 13.8 mM glucose] and 0.02% Pluronic F-127 for 60 min at 37°C. Cells were washed with
48
49 138 PBS, and then 90 μL of the recording buffer was added. After measuring baseline
50
51
52 139 fluorescence for 1 min, test compounds dissolved in the recording buffer (10 μL) were added
53
54 140 and changes in fluorescence (excitation 488 nm; emission 530 nm) were kinetically measured
55
56
57 141 by a microplate reader (SpectraMax i3, Molecular Devices, Sunnyvale, CA, USA) for 2 min.
58

59 142

2.4. Western blotting

After 1 h of CTD treatment, semi-confluent cells were dissolved in ice-cold lysis buffer [50 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 1% NP-40, supplemented with 1:1000 protease inhibitor cocktail and phosphatase inhibitor cocktail (Sigma-Aldrich)] and homogenized by an ultrasonic disruptor. Total protein concentrations of supernatant were determined using a Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA), and then equal amounts of proteins from each sample were boiled in SDS sample buffer [in final concentrations of 60 mM Tris /HCl, 10% glycerol, 2% SDS, 5% mercaptoethanol, 0.025% bromophenol blue, pH 6.8] at 94°C for 5 min. Samples containing 10 µg of protein extract were separated in SDS-polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked by PVDF Blocking Reagent for Can Get Signal (Toyobo Co., Ltd., Osaka, Japan) for 2 h at room temperature, and then incubated overnight at 4°C in Can Get Signal Immunoreaction Enhancer Solution 1 (Toyobo Co., Ltd.) with the rabbit anti-pERK antibody and mouse anti-ERK antibody (1:2000, #9101 and #9107, Cell Signaling Technology, Danvers, MA, USA). After washing 3 times with Tris-buffered saline containing 0.1% Tween 20, membranes were then incubated in Can Get Signal Immunoreaction Enhancer Solution 2 (Toyobo Co., Ltd.) with IRDye 680RD donkey anti-mouse IgG and IRDye 800CW goat anti-mouse IgG (1:2000; LI-COR Biosciences, Lincoln, NE, USA) for 2 h at room temperature. The Odyssey infrared imaging system (LI-COR Biosciences) was used to scan the infrared signal on membranes, and Image Studio 5.1 software (LI-COR Biosciences) was used to quantify the band intensity.

2.5. RNA isolation and Clariom S assay

After 24 h of 1 µM CTD treatment, total RNA was extracted from semi-confluent cells

1 167 using a NucleoSpin plus RNA isolation kit (Macherey-Nagel GmbH & Co., Düren, Germany)
2
3 168 following the manufacturer's instructions. The quality of the RNA was analyzed using a
4
5 169 Bioanalyzer 2100 and an RNA6000 Nano LabChip kit (Agilent Technologies, Inc., Santa
6
7
8 170 Clara, CA, USA) and samples with RIN (RNA integrity number) values above 9.8 were
9
10
11 171 considered acceptable. All RNA samples (500 ng) were amplified and labeled using the
12
13 172 GeneChip WT PLUS Reagent Kit and hybridized with the Clariom S human arrays
14
15
16 173 containing 21,448 probe sets (Affymetrix, Inc., Santa Clara, CA, USA). All microarrays were
17
18 174 washed and stained on the GeneChip Fluidics Station 450 using the GeneChip Hybridization,
19
20
21 175 Wash, and Stain Kit, and then scanned on the GeneChip Scanner 3000 (Affymetrix, Inc.). The
22
23 176 raw intensity data were normalized and analyzed using GeneSpring GX 14.9 software
24
25
26 177 (Agilent Technologies, Inc.). To examine the molecular functions of differentially expressed
27
28 178 genes, data were analyzed using Ingenuity Pathways Analysis (IPA) tools (Ingenuity Systems,
29
30
31 179 Mountain View, CA, USA). The microarray data (.CEL files) were deposited in a public
32
33
34 180 database (Gene Expression Omnibus, accession number: GSE126103).
35

36 181

39 182 *2.6. Quantitative reverse transcription PCR*

41 183 RNA samples (1 µg) were reverse-transcribed to cDNA using a PrimeScript RT Master
42
43
44 184 Mix (Takara Bio Inc., Shiga, Japan) following the manufacturer's instructions. Gene
45
46 185 expression was quantified using SYBR Green Premix Ex Taq II (Takara Bio Inc.) with
47
48
49 186 specific primers (Table 1) on an Mx3005P Real-Time QPCR System (Agilent Technologies,
50
51
52 187 Inc.). Cycling conditions were as follows: An initial degeneration of 95°C for 30 sec,
53
54 188 followed by 40 cycles of denaturing at 95°C for 5 sec, annealing at 55°C for 30 sec, and
55
56
57 189 elongation at 72°C for 30 sec. Copy number of genes were calculated by standard curves and
58
59 190 the relative gene expression levels are normalized by a housekeeping gene,
60

1 191 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a MxPro software (version 4.10,
2
3 192 Agilent Technologies, Inc.). All samples were measured in duplicate and the specificity of the
4
5
6 193 PCR products was confirmed by melting curves.
7

8 194

11 195 *2.7. Neurite outgrowth assay*

13 196 Cells were plated on glass coverslips precoated with poly-L-lysine in 24-well plates at a
14
15
16 197 seeding density of 5.0×10^4 cells/mL with 500 μ L of the culture medium. For differentiation,
17
18 198 cells were treated with FBS-free DMEM containing 10 μ M all-trans retinoic acid
19
20
21 199 (Sigma-Aldrich) for 3 days, followed by FBS-free DMEM containing 50 ng/mL of
22
23 200 brain-derived neurotrophic factor (Alomone lab, Jerusalem, Israel) for 3 days with or without
24
25
26 201 1 or 100 μ M CTD. After washing with PBS, cells were immediately fixed by 4%
27
28
29 202 paraformaldehyde for 10 min and then permeabilized in 0.1% Triton-X in PBS for 10 min.
30
31 203 Cells were blocked for 1 h with Blocking One Histo (Nacalai Tesque, Inc., Kyoto, Japan) and
32
33
34 204 then incubated overnight at 4°C in Can Get Signal Immunoreaction Enhancer Solution A
35
36 205 (Toyobo Co., Ltd.) with rabbit anti-MAP2 antibody (1:200, #4542, Cell Signaling
37
38
39 206 Technology). After washing 3 times with PBS containing 0.1% Tween 20, cells were
40
41
42 207 incubated for 2 h in Can Get Signal Immunoreaction Enhancer Solution B (Toyobo Co., Ltd.)
43
44 208 with anti-rabbit donkey IgG (H&L) antibody conjugated to DyLight 549 (1:1000,
45
46
47 209 #611-742-127, Rockland Immunochemicals, Inc., Gilbertsville, PA, USA). Cell nucleus was
48
49 210 counterstained with 4'-6-diamidino-2-phenylindole (DAPI). The coverslips were mounted on
50
51
52 211 microscope slides in ProLong Glass antifade mountant (Thermo Fisher Scientific, Waltham,
53
54 212 MA, USA) and fluorescence images were acquired with a BX61/DP70 microscope (Olympus,
55
56
57 213 Tokyo, Japan). Neurite length was measured in at least 100 cells in three randomly chosen
58
59 214 fields using ImageJ software (version 1.51) with the NeuronJ plugin.
60

1 215

3 216 2.8. *Statistical analyses*

6 217 Results from at least three independent experiments are expressed as the mean \pm standard
7
8 218 deviation (SD). IBM SPSS statistics 23 software (IBM Co., Somers, NY, USA) was used to
9
10 219 perform statistical analyses. The dose-response curve was fitted using the sigmoidal
11
12 220 (4-parameter) equation with JMP13 Pro software (SAS Institute, Cary, NC, USA). The EC50
13
14 221 value was calculated by determining the concentration at which 50% of maximum activity
15
16 222 was reached using the sigmoidal fit equation. One-way analysis of variance (ANOVA)
17
18 223 followed by Dunnett's post-hoc test was used to analyze the effects of CTD. Two-way
19
20 224 ANOVA followed by Tukey's post hoc test was used to analyze the interaction between CTD
21
22 225 and nAChR antagonists. The Welch's *t* test was used to validate the microarray results by
23
24 226 quantitative reverse transcription PCR. The results were considered significant when the
25
26 227 *p*-value was less than 0.05.
27
28
29
30
31
32

34 228

36 229 **3. Result**39 230 *3.1. Effects of CTD on the cell number of SH-SY5Y cells*

41 231 To determine the potential effects of CTD on human neuroblastoma SH-SY5Y cells, the
42
43 232 cell growth assays were conducted. As shown in Fig. 1A, CTD dose-dependently stimulated
44
45 233 the cell growth and one-way ANOVA showed that there were significant differences at Day 1
46
47 234 [F(2, 12) = 11.150, *p* < 0.01] and Day 2 [F(2, 12) = 5.764, *p* < 0.05]. The high concentration
48
49 235 of CTD (100 μ M) significantly increased the relative cell number at Day 1 (*p* < 0.01) and
50
51 236 Day 2 (*p* < 0.05). Low concentrations of CTD (1 μ M) also increased the relative cell number
52
53 237 at Day 1 (*p* < 0.05), but not significantly at Day 2. The dose-response relationship between
54
55 238 the exposure concentration and the growth stimulating effect of CTD was evaluated by the
56
57
58
59
60

1 239 WST-8 assay. The dose-response curves showed that CTD had growth stimulating effects on
2
3 240 SH-SY5Y cells with an EC50 of 577 nM (Fig. 1B).
4

5
6 241

7 8 242 *3.2. Antagonists to nAChR blocked the growth stimulating effect of CTD on SH-SY5Y cells*

9

10
11 243 We therefore investigated whether the effects of CTD on the SH-SY5Y cells were
12
13 244 mediated by human-type nAChRs. Although 10 μ M mecamylamine (MEC), a broad
14
15
16 245 spectrum non-competitive nAChRs antagonist, had no effect on the SH-SY5Y cells alone, it
17
18 246 inhibited the growth stimulating effect of 100 μ M CTD (Fig. 2A). Two-way ANOVA showed
19
20
21 247 that there was no effect of MEC [$F(1, 16) = 3.295$] and significant effect of CTD [$F(1, 16) =$
22
23 248 $7.853, p < 0.05$] and significant interaction [$F(1, 16) = 12.887, p < 0.01$]. According to a
24
25
26 249 previous report showing that SH-SY5Y cells are known to express $\alpha 3, \alpha 7, \beta 2$ and $\beta 4$ subunit
27
28
29 250 of nAChRs (Groot Kormelink and Luyten, 1997), we further examined which subunit of
30
31 251 nAChRs is involved in the effects of CTD with using subunit specific competitive nAChR
32
33
34 252 antagonists. As shown in Fig. 2B and 2C, the $\alpha 7$ and $\beta 2$ subunit specific antagonists
35
36 253 methyllycaconitine (MLA, 100 nM) and dihydro- β -erythroidine (DH β E, 10 μ M) did not
37
38
39 254 suppress the effects of CTD. There was no effect of antagonists [MLA: $F(1, 16) = 1.964$;
40
41 255 DH β E: $F(1, 16) = 4.191$], and significant effects of CTD were observed [MLA: $F(1, 16) =$
42
43 256 $15.817, p < 0.01$; DH β E: $F(1, 16) = 16.005, p < 0.01$]. No interaction was detected between
44
45
46 257 CTD and antagonists [MLA: $F(1, 16) = 4.743$; DH β E: $F(1, 16) = 0.009$]. In contrast, an $\alpha 3\beta 4$
47
48
49 258 specific antagonist, SR 16584 (10 μ M), blocked the effect induced by 100 μ M CTD (Fig. 2D).
50
51
52 259 Two-way ANOVA showed that there was no effect of SR 16584 [$F(1, 16) = 2.602$] and
53
54 260 significant effect of CTD [$F(1, 16) = 10.179, p < 0.05$] and significant interaction [$F(1, 16) =$
55
56
57 261 $8.312, p < 0.05$].
58

59 262

3.3. CTD evoked intracellular calcium flux in SH-SY5Y cells

As nAChRs are ligand-gated ion channels permeable to calcium ions, we next evaluate the CTD-induced changes of intracellular calcium levels in SH-SY5Y cells loaded with calcium-sensitive dye Fluo-4 AM. The temporal changes of intracellular calcium levels were monitored by fluorescence intensity of fluo-4 (F) normalized to the average of baseline intensity (F₀). As shown in Fig. 3A, transient increases of fluorescence intensity were observed immediately after exposure to CTD. Quantitative analyses showed that both the maximum amplitude (F_{max}-F₀) [F(3, 11) = 5.674, $p < 0.05$] and the area under the curve [F(3, 11) = 8.415, $p < 0.01$] were significantly increased by at least 10 μ M of CTD (Fig. 3B and 3C).

3.4. Effects of CTD on phosphorylation levels of ERK in SH-SY5Y cells

To examine the modulation of the intracellular signaling subsequent to intracellular calcium influx induced by CTD, we analyzed phosphorylation levels of extracellular signal-regulated kinase 1/2 (ERK), which is known to be important in proliferation of neuroblastoma cells (Stafman and Beierle, 2016). SH-SY5Y cells were exposed to CTD for 1 h, and total and phosphorylated ERK were detected on the same membrane at once by western blotting. As shown in Fig. 4A, although the band intensity of total ERK did not change, CTD increased that of phosphorylated ERK (p-ERK) compared to the control samples. Quantitative analyses showed that CTD dose-dependently and significantly increased the p-ERK/ERK ratio [F(3, 11) = 4.053, $p < 0.05$] (Fig. 4B).

3.5. Effects of CTD on global gene expression of SH-SY5Y cells

To understand changes of gene expression involved in the mechanisms of effects of CTD,

1 287 the transcriptome analysis was performed in cells exposed to 1 μ M CTD for 24 h using
2
3 288 GeneChip system and the clariom S human array with 21,448 probe sets. After normalization
4
5 289 of obtained intensities of probes using the RMA algorithm using the GeneSpring software,
6
7
8 290 low intensity probes (<10% expression level) were cutoff as noise. We then identified
9
10
11 291 differentially expressed genes (174 up-regulated and 151 down-regulated) with at least
12
13 292 1.5-fold change compared with the control group (0.1% DMSO), and then conducted
14
15
16 293 bioinformatical analyses to reveal biological functions, canonical pathways, and networks of
17
18 294 differentially expressed genes based on Ingenuity Pathway Analysis (IPA) knowledge base
19
20
21 295 software. We obtained little findings related to the phenotypic changes observed in this study
22
23
24 296 from up-regulated genes (Supplemental Materials). The top 25 biological functions with
25
26 297 positive z-scores related to the down-regulated genes are summarized in Table 2. Notably,
27
28
29 298 CTD significantly decreased the expression of genes associated with neural functions with
30
31 299 annotations of “Formation of filopodia,” “Brain lesion,” “Quantity of neurons,” “Behavior,”
32
33
34 300 and “Differentiation of nervous system.” Additionally, multiple annotations associated with
35
36 301 calcium signaling, “Flux of Ca^{2+} ,” “Influx of Ca^{2+} ,” and “Ion homeostasis of cells,” were also
37
38
39 302 listed. The differentially activated or suppressed canonical pathways in down-regulated genes
40
41 303 are shown in Fig. 5A. Canonical pathways including “Axonal Guidance Signaling” and
42
43
44 304 “Synaptic Long Term Depression” relating to neural function were enriched in
45
46 305 down-regulated genes. Cytoskeletal pathways, “G α 12/13 Signaling,” “PAK Signaling,”
47
48
49 306 “Actin Cytoskeleton Signaling,” and “Signaling by Rho Family GTPases,” were significantly
50
51
52 307 suppressed. Network analyses revealed gene networks with 40 molecules involved in
53
54 308 “Cardiovascular System Development and Function,” “Organismal Development” and
55
56
57 309 “Cell-To-Cell Signaling and Interaction” (Fig. 5B) and several down-regulated genes
58
59 310 indirectly affected signal transduction molecules such as ERK, ras-related protein 1 (Rap1)

1 311 and cAMP response element binding protein (Creb).
2

3 312
4

5 313 *3.6. Validation of microarray results by quantitative reverse transcription PCR* 6 7

8 314 To confirm the microarray results, the expression levels of down-regulated genes were
9
10 315 measured by quantitative reverse transcription PCR. We chose three genes significant in the
11
12 316 bioinformatical analyses by the IPA software including neuronal differentiation 4
13
14 317 (NEUROD4), adrenoceptor beta 2 (ADRB2), and neurotensin (NTS). As shown in Fig. 6,
15
16 317 (NEUROD4), adrenoceptor beta 2 (ADRB2), and neurotensin (NTS). As shown in Fig. 6,
17
18 318 quantitative results showed that 1 μM of CTD significantly suppressed the expression of
19
20 319 these genes ($p < 0.05$), which were the same pattern in microarray results.
21
22
23
24 320

25 26 321 *3.7. Effects of CTD on neurite outgrowth of SH-SY5Y cells* 27

28 322 In order to examine the neurodifferentiative effects of micromolar concentrations of CTD,
29
30 323 we treated differentiating cells with CTD and morphologically evaluated the neurite
31
32 324 outgrowth. As shown in Fig. 7A, neurites in differentiated cells were visualized by
33
34 324 outgrowth. As shown in Fig. 7A, neurites in differentiated cells were visualized by
35
36 325 immunofluorescent staining with the neurite marker MAP2 (microtubule-associated protein
37
38 326 2). Quantitative analyses revealed that at least 1 μM of CTD significantly increased neurite
39
40 327 length compared to the control group (Fig. 7B) [$F(3, 13) = 12.711, p < 0.01$]. The number of
41
42 327 length compared to the control group (Fig. 7B) [$F(3, 13) = 12.711, p < 0.01$]. The number of
43
44 328 neurites per cell was not significantly changed by CTD (Fig. 7C) [$F(3, 13) = 3.345$].
45
46 329

47 329 48 49 330 **4. Discussion** 50

51 331 In the present study, we investigated whether CTD affected human neuroblastoma
52
53 332 SH-SY5Y cells to obtain information about the risks of neonicotinoids in the human nervous
54
55 332 SH-SY5Y cells to obtain information about the risks of neonicotinoids in the human nervous
56
57 333 system. Unexpectedly, CTD dose-dependently increased the number of cells and nAChR
58
59 334 antagonists inhibited the growth stimulating effect of CTD. We clarified some of the
60
61
62
63
64
65

1 335 underlying mechanisms of the effects of CTD mediating intracellular calcium flux,
2
3 336 phosphorylation of signal transduction molecules and alteration of global gene expression.
4
5 337 Although cytotoxic effects of millimolar concentrations of neonicotinoids on SH-SY5Y cells
6
7
8 338 were previously reported (Skandrani et al., 2006; Şenyildiz et al., 2018), these results firstly
9
10
11 339 demonstrated that micromolar concentrations have functional effects on human-derived
12
13 340 neuronal cells, in part by changing the intracellular signaling. Taken together, our data would
14
15
16 341 provide a new perspective into understanding the effects of non-lethal doses of
17
18 342 neonicotinoids on human nervous systems.

21 343 One of the interesting findings of this study is the growth stimulating effects of CTD,
22
23 344 consistent with previous work evaluating the effects of nicotine in the same cell line (Serres
24
25
26 345 and Carney, 2006). At the cellular level, cholinergic signaling by exogenous stimulation
27
28
29 346 regulates cellular activities such as apoptosis, cell survival, proliferation and differentiation
30
31 347 (Resende and Adhikari, 2009). Excessive amounts of nicotinic agonists are lethal, but
32
33
34 348 sublethal doses consistently had proliferative effects in nAChR-expressing cell lines such as
35
36 349 HT29 colon cancer cells and A549 lung cancer cells (Wong et al., 2007; Mucchietto et al.,
37
38
39 350 2018). Additionally, activation of nAChRs has neuroprotective effects in SH-SY5Y cells; for
40
41 351 example, nAChRs activation alleviated neurotoxicity of okadaic acid and amyloid- β (Del
42
43
44 352 Barrio et al., 2011; Xue et al., 2015). Although the proliferation of neural cells was observed
45
46
47 353 in limited areas in the mature brain, an *in vivo* study showed that an $\alpha 7$ nicotinic agonist
48
49 354 reactivated adult neurogenesis in cortex and hippocampus in mice (Narla et al., 2013). Taken
50
51
52 355 together, further studies should be carried out focusing on the effects of neonicotinoids on
53
54 356 proliferative and differentiative neural stem cells in developing brains.

57 357 Our results showed that concomitant exposure to nAChR antagonists inhibited the growth
58
59 358 stimulating effects of CTD. Given that these antagonists are active against human nAChRs,
60

1 359 our findings raise the likelihood that human-type nAChRs could be affected by
2
3 360 neonicotinoids. Neuronal nAChRs are composed of pentamer structure and largely divided
4
5
6 361 into four groups by subunit composition: (i) $\alpha 7$ homomers, (ii) $\alpha 4$ and $\beta 2$ heteromers, (iii) $\alpha 3$,
7
8 362 $\beta 4$ and $\beta 2$ heteromers and (iv) $\alpha 2$, $\alpha 4$ and $\beta 4$ heteromers (Albuquerque et al., 2009). To date,
9
10
11 363 previous studies have reported that CTD modulates electrophysiological responses to
12
13 364 acetylcholine in human embryonic kidney (HEK293) cells expressing human $\alpha 4\beta 2$ nAChRs,
14
15
16 365 and in *Xenopus* oocytes expressing rat $\alpha 7$ nAChRs (Li et al., 2011; Cartereau et al., 2018). In
17
18 366 this study, we used human neuroblastoma SH-SY5Y cells expressing $\alpha 3$, $\alpha 7$, $\beta 2$, and $\beta 4$
19
20
21 367 subunits (Groot Kormelink and Luyten, 1997). Our results showed that mecamylamine and
22
23 368 SR 16584 inhibited the increasing of the cell number, indicating that $\alpha 3\beta 4$ nAChRs are
24
25
26 369 largely responsible for the effects of CTD. As described above, $\alpha 3\beta 4$ nAChRs are frequently
27
28
29 370 called “ganglion type” nAChRs, but they also play important roles in broad regions of
30
31 371 mammal brain including hippocampus, medial habenula, pineal gland, cerebellum, locus
32
33
34 372 coeruleus, substantia nigra and ventral tegmental area (Gotti, et al., 2006). Compared to other
35
36 373 types of nAChRs, the current responses of $\alpha 3\beta 4$ nAChRs to nicotinic agonists are slow but
37
38
39 374 strong and durable (Chavez-Noriega et al., 1997), which may lead to the functional effects
40
41
42 375 and phenotypic changes observed in this study. A recent study also revealed that the
43
44 376 neonicotinoid IMI facilitates the expression of tyrosine hydroxylase, a marker of
45
46
47 377 differentiation in PC12D cells mediated by rat $\alpha 3\beta 4$ and $\alpha 7$ nAChRs (Kawahata and
48
49 378 Yamakuni, 2018); thus, human $\alpha 3\beta 4$ nAChRs could be significant to understanding the
50
51
52 379 unexpected effects of neonicotinoids.

53
54 380 Neuronal nAChRs function as non-selective cation channels permeable to calcium ions.
55
56
57 381 Cation influx by nAChRs subsequently raises the intracellular calcium concentration by
58
59 382 activating voltage-dependent calcium channels (VDCCs) with membrane depolarization and

1 383 calcium release by ryanodine receptors from endoplasmic reticulum (Shen and Yakel, 2009).
2
3 384 In this study, micromolar concentrations of CTD dose-dependently evoked the transient
4
5 385 increase of intracellular calcium level for a few tens of seconds. These temporal patterns are
6
7
8 386 very similar to intracellular calcium responses to micromolar concentrations of nicotine; such
9
10
11 387 responses are partly mediated by $\alpha 7$ nAChRs and depend to a large part on VDCCs
12
13 388 (Dajas-Bailador et al., 2002a; Gilbert et al., 2009). Transcriptome analysis by Kimura-Kuroda
14
15
16 389 et al., (2016) showed that 1 μ M nicotine and two neonicotinoids (ACE and IMI) commonly
17
18 390 altered the gene expression of VDCC subunits in rat cerebellar cells. Another *in vivo* study
19
20
21 391 consistently demonstrated that CTD-induced dopamine release in rat striatum is related to
22
23 392 neuronal membrane depolarization (Faro et al., 2012). Our result also showed that gene sets
24
25
26 393 related “Flux of Ca^{2+} ,” “Influx of Ca^{2+} ,” and “Ion homeostasis of cells” were significantly
27
28
29 394 enriched in the CTD-down-regulated genes, which may be a result of negative feedback by
30
31 395 sustained higher intracellular calcium with membrane depolarization.
32

33
34 396 Mitogen-activated protein kinases play crucial roles in neural cells for transmitting
35
36 397 exogenous stimulation to intracellular signaling. In particular, ERK regulates cell
37
38
39 398 proliferation, differentiation, survival, and migration. In this study, we found that CTD
40
41
42 399 dose-dependently increased the phosphorylation level of ERK, consistent with other studies
43
44 400 in mouse neuroblastoma N1E-115 cells (Tomizawa and Casida, 2002) and SH-SY5Y cells
45
46
47 401 (Dajas-Bailador et al., 2002b). These studies consistently demonstrated that phosphorylation
48
49 402 states of ERK were altered by nAChR-mediated calcium signaling and membrane
50
51
52 403 depolarization. In rat PC12h cells, ERK phosphorylation by nicotinic ligands is inhibited by
53
54 404 $\alpha 3\beta 4$ nAChRs (Nakayama et al., 2006) and over-expression of $\alpha 7$ nAChRs promotes the
55
56
57 405 basal level of p-ERK (Utsugisawa et al., 2002). Our network analyses showed that most of
58
59
60 406 the down-regulated genes indirectly act upstream of ERK, which may support the modulation
61

1 407 of ERK activation induced by CTD. It also should be noted that neonicotinoids, including
2
3 408 CTD are immediately metabolized inside the body of mammals, and certain amounts of
4
5 409 metabolites of neonicotinoids are detected in the brain (Fold and Casida, 2006). Other studies
6
7
8 410 demonstrated that metabolites of IMI had higher affinity for human nAChRs and induced
9
10
11 411 strong activation of ERK than that of the original compound (Tomizawa and Casida 2002,
12
13 412 2005), indicating that additional studies should be conducted focusing on the potential effects
14
15
16 413 of metabolites of neonicotinoids. Considering that ERK signaling controls neuroplasticity and
17
18 414 synaptic transmission in the brain (Thomas and Huganir, 2004), we should consider the risks
19
20
21 415 of neonicotinoids on higher brain function such as learning and memory.

22
23 416 Microarray analyses revealed different aspects of the effects of CTD, indicating that 24 h
24
25
26 417 exposure of 1 μ M CTD could disrupt several sets of gene expression involved in cytoskeleton
27
28
29 418 regulatory signaling. A series of studies recently showed that $\alpha 7$ nAChRs coupled to
30
31 419 G-proteins and regulated cytoskeletal dynamics and axon growth (King et al., 2015; Kabbani
32
33
34 420 and Nichols, 2018), suggesting intracellular calcium flux mediated by nAChRs also
35
36 421 associated with morphological changes of neuronal cells. In this study, our data indicated that
37
38
39 422 down-regulated genes contained significantly enriched biological functions of “Formation of
40
41 423 filopodia,” essential for advancing growth cones to extend neurites at the tip of the axon. It
42
43
44 424 was also noted that “Axon guidance signaling” was the most significantly enriched pathway
45
46
47 425 with no activity pattern available and “Differentiation of nervous system” was the
48
49 426 significantly enriched biological function in the down-regulated genes by CTD. Therefore,
50
51
52 427 we investigated whether CTD had an impact on neurite outgrowth in differentiating
53
54 428 SH-SY5Y cells. We observed increased length and number of neurite in differentiated
55
56
57 429 SH-SY5Y cells by CTD exposure, both of which disagree with previous studies reporting that
58
59 430 ACE and IMI suppressed neurite outgrowth in rat Purkinje cells (Kimura-Kuroda et al., 2016).

1 431 Furthermore, another study reported that four neonicotinoids had no effect on neurite length
2
3 432 of PC12 cells (Christen et al., 2017). Nordman and Kabbani (2012) showed that nicotinic
4
5 433 agonists inhibited neurite surface area in PC12 cells, whereas a nicotinic antagonist for $\alpha 7$
6
7
8 434 nAChRs, α -bungarotoxin promoted it. These inconsistencies among studies may reflect
9
10
11 435 differences in species, cell type, and receptor properties.

12
13 436 In conclusion, the present study demonstrated for the first time that CTD had functional
14
15
16 437 effects on human neuroblastoma SH-SY5Y cells that resulted in increased cell growth
17
18 438 mediated by human nAChRs. Moreover, our data showed that micromolar concentrations of
19
20
21 439 CTD acutely disrupted intracellular signaling that led to an influx of intracellular calcium,
22
23
24 440 phosphorylation of ERK and alteration of global gene expression. Transcriptional and
25
26 441 neuromorphological changes strongly suggest that CTD has impacts on neuronal
27
28
29 442 differentiation and neurite outgrowth. Taken together, our data provide novel toxicological
30
31
32 443 information to assess the risk of neonicotinoids on human health by using a human-derived
33
34 444 cell line with neuronal properties. Additional research is needed to understand the risk of
35
36 445 environmentally-relevant doses of neonicotinoids, with a focus on developmental events in
37
38
39 446 the brain such as neural differentiation, migration, and neural circuit development.

40 41 447 42 43 44 448 **Conflict of interest**

45
46 449 The authors declare that they have no conflict of interest.
47
48

49 450 50 51 451 **Funding**

52 452 This work was supported by a Grant-in-Aid for Research Activity Start-up (JSPS
53
54
55
56 453 KAKENHI Grant Number JP17H06706) and a Grant-in-Aid for Early-Career Scientists
57
58
59 454 (JP19K19406) to T Hirano.
60

1 455

2

3 456 **Acknowledgments**

4

5
6 457 The authors thank all members of the life science research center for their technical

7

8 458 assistance.

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

459 **References**

- 1 460
2 461 Albuquerque, E. X., Pereira, E. F., Alkondon, M., Rogers, S. W., 2009. Mammalian nicotinic
3 462 acetylcholine receptors: from structure to function. *Physiol. Rev.* 89, 73–120.
4 463 Anderson, D. J., Bunnelle, W., Surber, B., Du, J., Surowy, C., Tribollet, E., Marguerat, A.,
5 464 Bertrand, D., Gopalakrishnan, M., 2008. [³H]A-585539
6 465 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane],
7 466 a novel high-affinity $\alpha 7$ neuronal nicotinic receptor agonist: radioligand binding
8 467 characterization to rat and human brain. *J. Pharmacol. Exp. Ther.* 324, 179–187.
9 468 Burke, A. P., Niibori, Y., Terayama, H., Ito, M., Pidgeon, C., Arsenault, J., Camarero, P. R.,
10 469 Cummins, C. L., Mateo, R., Sakabe, K., Hampson, D. R., 2018. Mammalian
11 470 susceptibility to a neonicotinoid insecticide after fetal and early postnatal exposure. *Sci.*
12 471 *Rep.* 8, 16639.
13 472 Cartereau, A., Martin, C., Thany, S. H., 2018. Neonicotinoid insecticides differently modulate
14 473 acetylcholine-induced currents on mammalian $\alpha 7$ nicotinic acetylcholine receptors. *Br. J.*
15 474 *Pharmacol.* 175, 1987–1998.
16 475 Casida, J. E., 2018. Neonicotinoids and other insect nicotinic receptor competitive
17 476 modulators: progress and prospects. *Annu. Rev. Entomol.* 63, 125–144.
18 477 Chavez-Noriega, L. E., Crona, J. H., Washburn, M. S., Urrutia, A., Elliott, K. J., Johnson, E.
19 478 C., 1997. Pharmacological characterization of recombinant human neuronal nicotinic
20 479 acetylcholine receptors $\alpha 2\beta 2$, $\alpha 2\beta 4$, $\alpha 3\beta 2$, $\alpha 3\beta 4$, $\alpha 4\beta 2$, $\alpha 4\beta 4$ and $\alpha 7$ expressed
21 480 in *Xenopus* oocytes. *J. Pharmacol. Exp. Ther.* 280, 346–356.
22 481 Chen, M., Tao, L., McLean, J., Lu, C., 2014. Quantitative analysis of neonicotinoid
23 482 insecticide residues in foods: implication for dietary exposures. *J. Agric. Food Chem.* 62,
24 483 6082–6090.
25 484 Christen, V., Rusconi, M., Crettaz, P., Fent, K., 2017. Developmental neurotoxicity of
26 485 different pesticides in PC-12 cells *in vitro*. *Toxicol. Appl. Pharmacol.* 325, 25–36.
27 486 Cimino, A. M., Boyles, A. L., Thayer, K. A., Perry, M. J., 2017. Effects of neonicotinoid
28 487 pesticide exposure on human health: A systematic review. *Environ. Health Perspect.* 125,
29 488 155–162.
30 489 Dajas-Bailador, F. A., Mogg, A. J., Wonnacott, S., 2002a. Intracellular Ca^{2+} signals evoked by
31 490 stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells: contribution of
32 491 voltage-operated Ca^{2+} channels and Ca^{2+} stores. *J. Neurochem.* 81, 606–614.
33 492 Dajas-Bailador, F. A., Soliakov, L., Wonnacott, S., 2002b. Nicotine activates the extracellular
34 493 signal-regulated kinase 1/2 via the $\alpha 7$ nicotinic acetylcholine receptor and protein kinase
35 494 A, in SH-SY5Y cells and hippocampal neurones. *J. Neurochem.* 80, 520–530.
36 495 Dani, J. A., Bertrand, D., 2007. Nicotinic acetylcholine receptors and nicotinic cholinergic
37 496 mechanisms of the central nervous system. *Annu. Rev. Pharmacol. Toxicol.* 47, 699–729.
38 497 Del Barrio, L., Martín-de-Saavedra, M. D., Romero, A., Parada, E., Egea, J., Avila, J.,
39 498 McIntosh, J. M., Wonnacott, S., López, M. G., 2011. Neurotoxicity induced by okadaic
40 499 acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by $\alpha 7$
41 500 and $\beta 2$ nicotinic stimulation. *Toxicol. Sci.* 123, 193–205.
42 501 Faro, L. R., Oliveira, I. M., Durán, R., Alfonso, M., 2012. *In vivo* neurochemical
43 502 characterization of clothianidin induced striatal dopamine release. *Toxicology* 302,
44 503 197–202.
45 504 Ford, K. A., Casida, J. E., 2006. Unique and common metabolites of thiamethoxam,
46 505 clothianidin, and dinotefuran in mice. *Chem. Res. Toxicol.* 19, 1549–1556.

- 506 Gibbons, D., Morrissey, C., Mineau, P., 2015. A review of the direct and indirect effects of
1 507 neonicotinoids and fipronil on vertebrate wildlife. *Environ. Sci. Pollut. Res. Int.* 22,
2 508 103–118.
- 3
4 509 Gilbert, D., Lecchi, M., Arnaudeau, S., Bertrand, D., Demaurex, N., 2009. Local and global
5 510 calcium signals associated with the opening of neuronal $\alpha 7$ nicotinic acetylcholine
6 511 receptors. *Cell Calcium* 45, 198–207.
- 7
8 512 Gotti, C., Zoli, M., Clementi, F., 2006. Brain nicotinic acetylcholine receptors: native
9 513 subtypes and their relevance. *Trends Pharmacol. Sci.* 27, 482–491.
- 10 514 Groot Kormelink, P. J., Luyten, W. H., 1997. Cloning and sequence of full-length cDNAs
11 515 encoding the human neuronal nicotinic acetylcholine receptor (nAChR) subunits $\beta 3$ and
12 516 $\beta 4$ and expression of seven nAChR subunits in the human neuroblastoma cell line
13 517 SH-SY5Y and/or IMR-32. *FEBS Lett.* 400, 309–314.
- 14
15 518 Hirano, T., Yanai, S., Omotehara, T., Hashimoto, R., Umemura, Y., Kubota, N., Minami, K.,
16 519 Nagahara, D., Matsuo, E., Aihara, Y., Shinohara, R., Furuyashiki, T., Mantani, Y.,
17 520 Yokoyama, T., Kitagawa, H., Hoshi, N., 2015. The combined effect of clothianidin and
18 521 environmental stress on the behavioral and reproductive function in male mice. *J. Vet.*
19 522 *Med. Sci.* 77, 1207–1215.
- 20
21 523 Hirano, T., Yanai, S., Takada, T., Yoneda, N., Omotehara, T., Kubota, N., Minami, K.,
22 524 Yamamoto, A., Mantani, Y., Yokoyama, T., Kitagawa, H., Hoshi, N., 2018. NOAEL-dose
23 525 of a neonicotinoid pesticide, clothianidin, acutely induce anxiety-related behavior with
24 526 human-audible vocalizations in male mice in a novel environment. *Toxicol. Lett.* 282,
25 527 57–63.
- 26
27 528 Hoshi, N., Hirano, T., Omotehara, T., Tokumoto, J., Umemura, Y., Mantani, Y., Tanida, T.,
28 529 Warita, K., Tabuchi, Y., Yokoyama, T., Kitagawa, H., 2014. Insight into the mechanism
29 530 of reproductive dysfunction caused by neonicotinoid pesticides. *Biol. Pharm. Bull.* 37,
30 531 1439–1443.
- 31
32 532 Ikenaka, Y., Fujioka, K., Kawakami, T., Ichise, T., Bortey-Sam, N., Nakayama, S. M. M.,
33 533 Mizukawa, H., Taira, K., Takahashi, K., Kato, K., Arizono, K., Ishizuka, M., 2018.
34 534 Contamination by neonicotinoid insecticides and their metabolites in Sri Lankan black
35 535 tea leaves and Japanese green tea leaves. *Toxicol. Rep.* 5, 744–749.
- 36
37 536 Ikenaka, Y., Miyabara, Y., Ichise, T., Nakayama, S., Nimako, C., Ishizuka, M., Tohyama, C.,
38 537 2019. Exposures of children to neonicotinoids in pine wilt disease control areas. *Environ.*
39 538 *Toxicol. Chem.* 38, 71–79.
- 40
41 539 Kabbani, N., Nichols, R. A., 2018. Beyond the channel: metabotropic signaling by nicotinic
42 540 receptors. *Trends Pharmacol. Sci.* 39, 354–366.
- 43
44 541 Kawahata, I., Yamakuni, T., 2018. Imidacloprid, a neonicotinoid insecticide, facilitates
45 542 tyrosine hydroxylase transcription and phenylethanolamine *N*-methyltransferase mRNA
46 543 expression to enhance catecholamine synthesis and its nicotine-evoked elevation in
47 544 PC12D cells. *Toxicology* 394, 84–92.
- 48
49 545 Kimura-Kuroda, J., Komuta, Y., Kuroda, Y., Hayashi, M., Kawano, H., 2012. Nicotine-like
50 546 effects of the neonicotinoid insecticides acetamiprid and imidacloprid on cerebellar
51 547 neurons from neonatal rats. *PLoS One* 7, e32432.
- 52
53 548 Kimura-Kuroda, J., Nishito, Y., Yanagisawa, H., Kuroda, Y., Komuta, Y., Kawano, H.,
54 549 Hayashi, M., 2016. Neonicotinoid insecticides alter the gene expression profile of
55 550 neuron-enriched cultures from neonatal rat cerebellum. *Int. J. Environ. Res. Public*
56 551 *Health* 13, 987.
- 57
58 552 King, J. R., Nordman, J. C., Bridges, S. P., Lin, M. K., Kabbani, N., 2015. Identification and
59
60
61
62
63
64
65

- 553 characterization of a G protein-binding cluster in $\alpha 7$ nicotinic acetylcholine receptors. *J.*
 1 554 *Biol. Chem.* 290, 20060–20070.
- 2 555 Kovalevich, J., Langford, D., 2013. Considerations for the use of SH-SY5Y neuroblastoma
 3 556 cells in neurobiology. *Methods Mol. Biol.* 1078, 9–21.
- 4 557 Li, P., Ann, J., Akk, G., 2011. Activation and modulation of human $\alpha 4\beta 2$ nicotinic
 5 558 acetylcholine receptors by the neonicotinoids clothianidin and imidacloprid. *J. Neurosci.*
 6 559 *Res.* 89, 1295–1301.
- 7 560 Lukas, R. J., Norman, S. A., Lucero, L., 1993. Characterization of nicotinic acetylcholine
 8 561 receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. *Mol.*
 9 562 *Cell. Neurosci.* 4, 1–12.
- 10 563 Mucchietto, V., Fasoli, F., Pucci, S., Moretti, M., Benfante, R., Maroli, A., Di Lascio, S.,
 11 564 Bolchi, C., Pallavicini, M., Dowell, C., McIntosh, M., Clementi, F., Gotti, C., 2018. $\alpha 9$ -
 12 565 and $\alpha 7$ -containing receptors mediate the pro-proliferative effects of nicotine in the A549
 13 566 adenocarcinoma cell line. *Br. J. Pharmacol.* 175, 1957–1972.
- 14 567 Nakayama, H., Shimoke, K., Isosaki, M., Satoh, H., Yoshizumi, M., Ikeuchi, T., 2006.
 15 568 Subtypes of neuronal nicotinic acetylcholine receptors involved in nicotine-induced
 16 569 phosphorylation of extracellular signal-regulated protein kinase in PC12h cells. *Neurosci.*
 17 570 *Lett.* 392, 101–104.
- 18 571 Narla, S., Klejbor, I., Birkaya, B., Lee, Y. W., Morys, J., Stachowiak, E. K., Terranova, C.,
 19 572 Bencherif, M., Stachowiak, M. K., 2013. $\alpha 7$ nicotinic receptor agonist reactivates
 20 573 neurogenesis in adult brain. *Biochem. Pharmacol.* 86, 1099–1104.
- 21 574 Nordman, J. C., Kabbani, N., 2012. An interaction between $\alpha 7$ nicotinic receptors and a
 22 575 G-protein pathway complex regulates neurite growth in neural cells. *J. Cell Sci.* 125,
 23 576 5502–5513.
- 24 577 Osaka, A., Ueyama, J., Kondo, T., Nomura, H., Sugiura, Y., Saito, I., Nakane, K., Takaishi, A.,
 25 578 Ogi, H., Wakusawa, S., Ito, Y., Kamijima, M., 2016. Exposure characterization of three
 26 579 major insecticide lines in urine of young children in Japan— neonicotinoids,
 27 580 organophosphates, and pyrethroids. *Environ. Res.* 147, 89–96.
- 28 581 Papke, R. L., Porter Papke, J. K., 2002. Comparative pharmacology of rat and human $\alpha 7$
 29 582 nAChR conducted with net charge analysis. *Br. J. Pharmacol.* 137, 49–61.
- 30 583 Resende, R. R., Adhikari, A., 2009. Cholinergic receptor pathways involved in apoptosis, cell
 31 584 proliferation and neuronal differentiation. *Cell Commun. Signal.* 7, 20.
- 32 585 Sano, K., Isobe, T., Yang, J., Win-Shwe, T. T., Yoshikane, M., Nakayama, S. F., Kawashima,
 33 586 T., Suzuki, G., Hashimoto, S., Nohara, K., Tohyama, C., Maekawa, F., 2016. *In utero* and
 34 587 lactational exposure to acetamiprid induces abnormalities in socio-sexual and
 35 588 anxiety-related behaviors of male mice. *Front. Neurosci.* 10, 228.
- 36 589 Şenyildiz, M., Kilinc, A., Ozden, S., 2018. Investigation of the genotoxic and cytotoxic
 37 590 effects of widely used neonicotinoid insecticides in HepG2 and SH-SY5Y cells. *Toxicol.*
 38 591 *Ind. Health* 34, 375–383.
- 39 592 Serres, F., Carney, S. L., 2006. Nicotine regulates SH-SY5Y neuroblastoma cell proliferation
 40 593 through the release of brain-derived neurotrophic factor. *Brain Res.* 1101, 36–42.
- 41 594 Sheets, L. P., Li, A. A., Minnema, D. J., Collier, R. H., Creek, M. R., Peffer, R. C., 2016. A
 42 595 critical review of neonicotinoid insecticides for developmental neurotoxicity. *Crit. Rev.*
 43 596 *Toxicol.* 46, 153–190.
- 44 597 Shen, J. X., Yakel, J. L., 2009. Nicotinic acetylcholine receptor-mediated calcium signaling in
 45 598 the nervous system. *Acta Pharmacol. Sin.* 30, 673–680.
- 46 599 Skandrani, D., Gaubin, Y., Beau, B., Murat, J. C., Vincent, C., Croute, F., 2006. Effect of

- 600 selected insecticides on growth rate and stress protein expression in cultured human
601 A549 and SH-SY5Y cells. *Toxicol. In Vitro* 20, 1378–1386.
- 602 Stafman, L. L., Beierle, E. A., 2016. Cell proliferation in neuroblastoma. *Cancers (Basel)* 8,
603 13.
- 604 Stokes, C., Treinin, M., Papke, R. L., 2015. Looking below the surface of nicotinic
605 acetylcholine receptors. *Trends Pharmacol. Sci.* 36, 514–523.
- 606 Takada, T., Yoneda, N., Hirano, T., Yanai, S., Yamamoto, A., Mantani, Y., Yokoyama, T.,
607 Kitagawa, H., Tabuchi, Y., Hoshi, N., 2018. Verification of the causal relationship
608 between subchronic exposures to dinotefuran and depression-related phenotype in
609 juvenile mice. *J. Vet. Med. Sci.* 80, 720–724.
- 610 Thomas, G. M., Huganir, R. L., 2004. MAPK cascade signalling and synaptic plasticity. *Nat.*
611 *Rev. Neurosci.* 5, 173–183.
- 612 Tomizawa, M., Casida, J. E., 2002. Desnitro-imidacloprid activates the extracellular
613 signal-regulated kinase cascade via the nicotinic receptor and intracellular calcium
614 mobilization in N1E-115 cells. *Toxicol. Appl. Pharmacol.* 184, 180–186.
- 615 Tomizawa, M., Casida, J. E., 2005. Neonicotinoid insecticide toxicology: mechanisms of
616 selective action. *Annu. Rev. Pharmacol. Toxicol.* 45, 247–268.
- 617 Tsunoyama, K., Gojobori, T., 1998. Evolution of nicotinic acetylcholine receptor subunits.
618 *Mol. Biol. Evol.* 15, 518–527.
- 619 Ueyama, J., Harada, K. H., Koizumi, A., Sugiura, Y., Kondo, T., Saito, I., Kamijima, M.,
620 2015. Temporal levels of urinary neonicotinoid and dialkylphosphate concentrations in
621 Japanese women between 1994 and 2011. *Environ. Sci. Technol.* 49, 14522–14528.
- 622 Utsugisawa, K., Nagane, Y., Obara, D., Tohgi, H., 2002. Over-expression of $\alpha 7$ nicotinic
623 acetylcholine receptor induces sustained ERK phosphorylation and N-cadherin
624 expression in PC12 cells. *Brain Res. Mol. Brain Res.* 106, 88–93.
- 625 Wang, X., Anadón, A., Wu, Q., Qiao, F., Ares, I., Martínez-Larrañaga, M. R., Yuan, Z.,
626 Martínez, M. A., 2018. Mechanism of neonicotinoid toxicity: Impact on oxidative stress
627 and metabolism. *Annu. Rev. Pharmacol. Toxicol.* 58, 471–507.
- 628 Wong, H. P., Yu, L., Lam, E. K., Tai, E. K., Wu, W. K., Cho, C. H., 2007. Nicotine promotes
629 cell proliferation via $\alpha 7$ -nicotinic acetylcholine receptor and catecholamine-synthesizing
630 enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. *Toxicol. Appl.*
631 *Pharmacol.* 221, 261–267.
- 632 Xue, M., Zhu, L., Zhang, J., Qiu, J., Du, G., Qiao, Z., Jin, G., Gao, F., Zhang, Q., 2015. Low
633 dose nicotine attenuates A β neurotoxicity through activation early growth response gene
634 1 pathway. *PLoS One* 10, e0120267.
- 635 Yoneda, N., Takada, T., Hirano, T., Yanai, S., Yamamoto, A., Mantani, Y., Yokoyama, T.,
636 Kitagawa, H., Tabuchi, Y., Hoshi, N., 2018. Peripubertal exposure to the neonicotinoid
637 pesticide dinotefuran affects dopaminergic neurons and causes hyperactivity in male
638 mice. *J. Vet. Med. Sci.* 80, 634–637.

1 639 **Figure legends**

2
3 640 **Fig. 1.** Effects of clothianidin (CTD) on the cell growth of SH-SY5Y cells. (A) Cell growth
4
5
6 641 curve for SH-SY5Y cells exposed to 1 or 100 μM CTD. Relative cell number is determined
7
8 642 as fold change in cell number relative to the number of cells initially plated. (B)
9
10
11 643 Dose-response curve for the increases of cell number at 24 h of CTD exposure evaluated by
12
13 644 WST-8 assay. Responses are normalized to the maximum response induced by 10 μM CTD
14
15
16 645 and fitted to the 4-parameter sigmoidal equation. All data points are represented by at least
17
18 646 five independent experiments and values are shown by the mean \pm SD, $^\dagger p < 0.05$ CTD 1 μM
19
20
21 647 vs. control group, and $*p < 0.05$, $**p < 0.01$ CTD 100 μM vs. control group (one-way
22
23
24 648 ANOVA followed by Dunnett's post-hoc test).

25
26 649
27
28
29 650 **Fig. 2.** Effects of nicotinic acetylcholine receptors antagonists, (A) 10 μM mecamylamine
30
31 651 (MEC; broad spectrum antagonist), (B) 100 nM methyllycaconitine (MLA; $\alpha 7$ selective
32
33
34 652 antagonist), (C) 10 μM dihydro- β -erythroidine (DH β E; $\beta 2$ selective antagonist) and (D) 10
35
36 653 μM SR 16584 ($\alpha 3\beta 4$ selective antagonist) on the growth stimulating effect of 100 μM CTD.
37
38
39 654 All data are represented by at least five independent experiments and values are shown by the
40
41 655 mean \pm SD, $*p < 0.05$, $**p < 0.01$ vs. other groups (two-way ANOVA followed by Tukey's
42
43
44 656 post-hoc test).

45
46 657
47
48
49 658 **Fig. 3.** Effects of CTD on intracellular calcium level of SH-SY5Y cells evaluated by fluo-4
50
51 659 assay. (A) Time course of changes in the fluorescence intensity of fluo-4 evoked by CTD.
52
53
54 660 Fluorescence intensity at each time point was normalized to the average level of the baseline
55
56
57 661 intensity. The summarized data, (B) $F_{\text{max}}-F_0$ and (C) area under curve were calculated to
58
59 662 quantitate the effect of CTD. F: fluorescence intensity; F_0 : average level of baseline

1 663 fluorescence intensity; Fmax: maximal value of fluorescence intensity after treatment. All
 2
 3 664 data are represented by at least three independent experiments and values are shown by the
 4
 5 665 mean \pm SD, * p < 0.05, ** p < 0.01 vs. control group (one-way ANOVA followed by Dunnett's
 6
 7
 8 666 post-hoc test).

10 667

13 668 **Fig. 4.** Effects of CTD on phosphorylation levels of extracellular signal-regulated kinase 1/2
 14
 15
 16 669 (ERK) on SH-SY5Y cells analyzed by western blotting. (A) Representative images of bands
 17
 18 670 of phosphorylated ERK (p-ERK) and total ERK on the same membrane. (B) Phosphorylation
 19
 20
 21 671 levels of ERK after 1 h exposure of CTD were calculated by band intensities of p-ERK
 22
 23 672 normalized by those of total ERK. All data are represented by at least three independent
 24
 25
 26 673 experiments and values are shown by the mean \pm SD, * p < 0.05 vs. control group (one-way
 27
 28
 29 674 ANOVA followed by Dunnett's post-hoc test).

31 675

34 676 **Fig. 5.** Canonical pathways and a gene network of 151 down-regulated genes (>1.5-fold)
 35
 36 677 altered by 24 h exposure of 1 μ M CTD identified by ingenuity pathway analysis (IPA)
 37
 38
 39 678 software. (A) Signaling pathways significantly enriched by Fisher's exact test were
 40
 41 679 summarized. Solid and dotted squares showed pathways related to neural and cytoskeletal
 42
 43
 44 680 function. (B) A gene network map illustrated interactions of down-regulated genes (green
 45
 46 681 colored) and other molecules.

49 682

52 683 **Fig. 6.** Validation of microarray results using quantitative reverse transcription PCR. Gene
 53
 54 684 expression levels of neuronal differentiation 4 (NEUROD4), adrenoceptor beta 2 (ADRB2),
 55
 56
 57 685 neurotensin (NTS) in the control (white bar) and of CTD-exposed group (1 μ M, blue bar)
 58
 59 686 were calculated relative to the housekeeping gene, glyceraldehyde-3-phosphate

1 687 dehydrogenase (GAPDH) by comparison to the control group. All data are represented by at
2
3 688 least three independent experiments and values are shown by the mean \pm SD, * p < 0.05 vs.
4
5
6 689 control group (Welch's t test).

7
8 690

9
10
11 691 **Fig. 7.** Effects of CTD on neurite outgrowth in differentiating SH-SY5Y cells. Cells were
12
13 692 induced to differentiate for 6 days with or without CTD exposure. (A) Representative images
14
15
16 693 of immunofluorescent staining of a neurite maker, MAP2 (microtubule-associated protein 2:
17
18 694 red) with DAPI cell nuclear staining (blue) in the control, CTD 1 μ M, CTD 10 μ M and
19
20
21 695 CTD 100 μ M group. The average of (B) neurite length and (C) number of neurites per cell
22
23
24 696 were measured by the image analysis. Bar = 100 μ m. All data are represented by at least three
25
26 697 independent experiments and values are shown by the mean \pm SD, * p < 0.05, ** p < 0.01 vs.
27
28
29 698 control group (one-way ANOVA followed by Dunnett's post-hoc test).

Table1. Primer sequences used in quantitative reverse transcription PCR

Gene Symbol	Gene ID	Direction	Primer sequence (5'-3')
NEUROD4	NM_021191.3	foward	gggagagctagtagcaacacac
(neuronal differentiation 4)		reverse	ttgggaccccttctcttagg
ADRB2	NM_000024.5	foward	ggattgtgtcaggccttacc
(adrenoceptor beta 2)		reverse	gatcaccaggggaacgtaga
NTS	NM_006183.5	foward	ccttcagtgtgcttctgac
(neurotensin)		reverse	gcagagtcatttccaagag
GAPDH	NM_001256799.2	foward	ccaccaactgcttagcac
(glyceraldehyde-3-phosphate dehydrogenase)		reverse	catcacgccacagtttcc

Table 2. Top 25 of biological functions of 151 down-regulated genes

Functions Annotation	<i>p</i> -Value	Predicted Activation State	Activation z-score	Number of Molecules
Size of body	9.46E-05	Decreased	-4.088	18
Formation of filopodia	4.74E-03	Decreased	-2.219	5
Flux of Ca ²⁺	5.64E-03	Decreased	-2.192	7
Binding of leukocyte cell lines	4.57E-04	Decreased	-2.000	4
Hydrolysis of nucleotide	6.18E-03		-1.949	4
Influx of Ca ²⁺	1.17E-02		-1.932	5
Ion homeostasis of cells	5.18E-03		-1.890	11
Adhesion of blood cells	7.08E-03		-1.857	8
Adhesion of tumor cell lines	7.04E-03		-1.680	7
Adhesion of immune cells	1.51E-02		-1.598	7
Leukocyte migration	4.62E-03		-1.341	15
Permeability of vascular system	1.52E-04		-1.164	7
Angiogenesis of tumor	8.02E-03		-1.131	4
Binding of hematopoietic cell lines	5.26E-05		-1.109	5
Brain lesion	4.55E-03		-0.927	15
Atherosclerosis	4.39E-03		-0.878	10
Growth of vessel	7.45E-04		-0.796	6
Advanced malignant tumor	8.25E-03		-0.594	15
Quantity of neurons	1.16E-02		-0.527	8
Cancer of cells	1.29E-02		-0.384	46
Neoplasia of cells	4.51E-03		-0.350	49
Behavior	7.85E-03		-0.046	16
Lymphatic system tumor	8.34E-03		0.926	24
Differentiation of nervous system	1.42E-02		1.342	9
Organismal death	9.36E-03	Increased	4.755	30

activation z-score; >2.0 or < -2.0 is significantly predictive

699








Figure
[Click here to download high resolution image](#)






A






B






Figure

[Click here to download high resolution image](#)







Supplementary Material

[Click here to download Supplementary Material: Supplemental Materials _THirano.xlsx](#)